Clinical trial
Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of…
NCT00311415 · Novartis Vaccines, Industry · Completed
Key facts
| NCT number | NCT00311415 |
|---|---|
| Title | Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children |
| Official title | A Phase III, Multi-Center, Open-Label, Controlled, Randomized Study to Evaluate the Immunogenicity, Safety, Tolerability and the Ability to Prime for Memory of Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Infants as One Dose Given at 2 or 6 Months of Age With a Booster at… |
| Lead sponsor | Novartis Vaccines, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prevention of Meningococcal Infection |
| Intervention type | Biological |
| Interventions | Meningococcal C conjugate vaccine |
| Enrollment | 257 |
| Start date | Oct 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Apr 6, 2006 |
| Last update posted | Feb 8, 2012 |
| Countries | Germany, Poland |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: